Please ensure Javascript is enabled for purposes of website accessibility

3 Growth Stocks That'll Make You Richer By 2024

By Alex Carchidi – Sep 5, 2021 at 5:39AM

Key Points

  • Companies with recurring revenue are often more effective at expanding over time than those without.
  • Innovation is expensive, but it can pay off big over time.
  • New products can succeed by avoiding the longstanding, frustrating weaknesses of the competing options.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Their competition is in the rearview mirror, and customers are clamoring for their products.

Packing your portfolio with rapidly growing stocks is key, but it's all too easy to buy growth stocks that fizzle out after a couple of quarters. If you want to become more wealthy over the next few years and beyond, you'll need to identify companies that are supported by a handful of different trends and capabilities that reinforce their consistent and meaty growth. 

All three of the healthcare companies I'll discuss today are highly successful, and they're also escalating their revenue-making potential by building on their difficult-to-imitate products. While the largest gains will go to investors who hold these innovative companies for years, they're also moving quickly enough to make the time between now and 2024 quite exciting, so let's dive in.

A worker examines a medical device to perform a quality control check.

Image source: Getty Images.

1. Intuitive Surgical

Intuitive Surgical (ISRG -1.46%) sells robotic surgery units to hospitals around the world, and business is booming. Even amid the economic disruption of the pandemic, the company increased its base of installed systems by 10% between June 2020 and the same period in 2021. That's a strongly positive sign for Intuitive's future, as every installed robotic surgery system implies significant future revenue from maintenance and sales of fresh tools and accessories. In 2020, a stunning 77% of its revenue was recurring. 

And the more procedures that the robots perform per year, the more the hospitals end up spending. From the second quarter of 2019 until Q2 2021, the number of procedures performed by Intuitive's robots increased by a compound annual growth rate (CAGR) of 16.5%. In terms of revenue, that works out to a CAGR of 15% -- despite the near-total stoppage of elective surgical procedures amid the onset of the coronavirus pandemic. 

Moving forward, Intuitive will be looking to increase the rate of new system installations to make up for lost time in 2020. All the while, it'll be working on making new surgical tools and instruments to expand the range of procedures that its robots can perform. That will lead to higher revenue from existing customers, and it might serve to attract new buyers, too. 

While competitors may be starting to make inroads into the robotic surgery market, investors probably don't need to worry very much. Once hospitals have spent time and money training surgeons on a given surgical system, there's a high cost to switch to a competing product, so Intuitive can continue to make long-lasting headway even as competitors become more established. 

2. Align Technology

Align Technology (ALGN 1.08%) makes invisible, removable teeth straighteners that are comparable in function to braces. But the company's Invisalign-branded products are arguably much more aesthetically appealing than braces, which is no small ingredient in its recipe for success. 

By solving a key problem with a formerly dominant legacy product, Align has had an easy time finding prospective customers and gaining market share. Internet searches for doctors capable of fitting patients for Invisalign increased by 82% year over year in Q2. 

Align also sells imaging technology to dental care professionals, which they can use to fit their patients for the company's straighteners. So, it makes money first when customers want to have the ability to sell its main product, and then again when customers buy cases of straighteners to distribute to patients. And sales are hot: In the second quarter of 2021, revenue from imaging systems rose by a whopping 20% sequentially, and income from cases of aligners rose by 11.6% sequentially, making for more than $1 billion in total revenue for the period.

Finally, Align is slated to reward its shareholders by initiating an accelerated stock buyback program worth $75 million to speed up its existing buyback program that's budgeted for $1 billion. The accelerated buyback should be finished by late October, so expect some upward pressure on the stock price between now and then.

^SPX Chart

^SPX data by YCharts

3. DexCom

DexCom (DXCM -1.94%) develops continuous glucose monitors (CGMs) for people with type 2 diabetes. Unlike the traditional finger-stick method for measuring a person's glucose level, DexCom's CGMs use a disposable under-the-skin sensor that patients wear for 10-day intervals. Then, the sensor uploads data to a smartphone app, where patients can see their glucose levels in real time. That means patients can recognize when to take corrective action earlier, thereby better protecting their health and comfort -- and without needing to prick their finger multiple times per day. And when patients exhaust their supply of wearable sensors, they'll need to put in an order for another case. So there's a recurring component to DexCom's revenue base, which helps it grow more consistently.

Much like with Align Technologies, DexCom's product practically sells itself just because it doesn't have the fundamental flaws of the traditional option. Thus, it's no surprise that the company's total revenue grew by 32% year over year to reach $595 million in the second quarter of this year. What's more, management expects its gross profit margin to rise to 67%, an even larger increase than it initially predicted for 2021.

Before the end of the year, DexCom expects to launch the seventh edition of its CGM device. Meanwhile, management will be proceeding with international sales efforts in new major markets including France, Turkey, and India. Its stellar product, expanding revenue, and strengthening margins provide quite a lot for investors to like, and the next few years should be exciting for shareholders.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Align Technology and Intuitive Surgical. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Align Technology Stock Quote
Align Technology
ALGN
$191.83 (1.08%) $2.05
Intuitive Surgical Stock Quote
Intuitive Surgical
ISRG
$258.80 (-1.46%) $-3.84
DexCom Stock Quote
DexCom
DXCM
$110.39 (-1.94%) $-2.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.